Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?

The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals...

Full description

Saved in:
Bibliographic Details
Published in:Chemical communications (Cambridge, England) England), 2004-09 (17), p.1889-1896
Main Authors: Almarsson, Orn, Zaworotko, Michael J
Format: Article
Language:English
Subjects:
Acids - chemistry
Amides - chemistry
Carboxylic Acids - chemistry
Chemistry, Pharmaceutical - methods
Crystallization - methods
Crystallography
Drug Stability
Hydrogen Bonding
Molecular Structure
Organic Chemicals - chemistry
Pharmaceutical Preparations
Phase Transition
Technology, Pharmaceutical - instrumentation
Technology, Pharmaceutical - methods
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.
ISSN:1359-7345
1364-548X
DOI:10.1039/b402150a